Amgen: Growth Potential Met By High Debt Levels

Summary

• Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain.
• Despite high debt from the Horizon Therapeutics acquisition, Amgen shows growth potential through obesity drugs, biosimilars, and other pharmaceuticals.
• Amgen's balance sheet has slightly improved, but high debt levels and significant dividend payments remain concerns.
• While Amgen is not facing bankruptcy, I would prefer a lower stock price before considering an investment.